12.53
price up icon19.33%   2.03
pre-market  プレマーケット:  12.39   -0.14   -1.12%
loading
前日終値:
$10.50
開ける:
$14.4
24時間の取引高:
16.60M
Relative Volume:
9.73
時価総額:
$1.40B
収益:
$577.74M
当期純損益:
$-149.78M
株価収益率:
-8.95
EPS:
-1.4
ネットキャッシュフロー:
$-78.21M
1週間 パフォーマンス:
+24.18%
1か月 パフォーマンス:
-11.64%
6か月 パフォーマンス:
+10.49%
1年 パフォーマンス:
-41.37%
1日の値動き範囲:
Value
$12.01
$14.97
1週間の範囲:
Value
$9.82
$14.97
52週間の値動き範囲:
Value
$9.82
$22.95

Novocure Ltd Stock (NVCR) Company Profile

Name
名前
Novocure Ltd
Name
セクター
Healthcare (1112)
Name
電話
44 (0)15 3475 6700
Name
住所
NO. 4 THE FORUM, ST. HELIER
Name
職員
1,488
Name
Twitter
@novocure
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
NVCR's Discussions on Twitter

Compare NVCR vs ABT, SYK, MDT, BSX, EW

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Medical Devices icon
NVCR
Novocure Ltd
12.53 1.18B 577.74M -149.78M -78.21M -1.40
Medical Devices icon
ABT
Abbott Laboratories
111.47 197.52B 44.33B 6.48B 6.92B 3.7033
Medical Devices icon
SYK
Stryker Corp
365.85 139.09B 25.12B 3.25B 4.28B 8.4018
Medical Devices icon
MDT
Medtronic Plc
100.88 129.59B 34.76B 4.79B 5.21B 3.7017
Medical Devices icon
BSX
Boston Scientific Corp
74.12 108.96B 20.08B 2.89B 3.82B 1.9391
Medical Devices icon
EW
Edwards Lifesciences Corp
76.44 46.04B 6.07B 1.06B 799.60M 1.8527

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-25 ダウングレード Wells Fargo Overweight → Equal Weight
2025-07-08 開始されました Ladenburg Thalmann Buy
2024-12-02 アップグレード Evercore ISI In-line → Outperform
2024-10-16 アップグレード H.C. Wainwright Neutral → Buy
2023-11-20 再開されました JP Morgan Neutral
2023-08-28 ダウングレード H.C. Wainwright Buy → Neutral
2023-08-08 アップグレード Piper Sandler Neutral → Overweight
2023-08-04 開始されました SVB Securities Outperform
2023-07-31 アップグレード Evercore ISI Underperform → In-line
2023-06-07 アップグレード Wedbush Underperform → Neutral
2023-05-16 アップグレード Wells Fargo Equal Weight → Overweight
2023-03-17 ダウングレード JP Morgan Neutral → Underweight
2023-01-06 ダウングレード Wells Fargo Overweight → Equal Weight
2023-01-05 繰り返されました H.C. Wainwright Buy
2022-11-29 アップグレード Wells Fargo Equal Weight → Overweight
2022-10-24 ダウングレード Piper Sandler Overweight → Neutral
2022-07-05 ダウングレード Evercore ISI In-line → Underperform
2022-05-16 開始されました H.C. Wainwright Buy
2022-02-08 開始されました Loop Capital Buy
2022-02-02 アップグレード Oppenheimer Perform → Outperform
2022-01-20 アップグレード Truist Hold → Buy
2022-01-03 アップグレード Evercore ISI Underperform → In-line
2021-07-01 ダウングレード Mizuho Buy → Neutral
2021-04-14 ダウングレード Wedbush Neutral → Underperform
2021-01-25 繰り返されました Piper Sandler Overweight
2020-09-23 開始されました Northland Capital Outperform
2020-09-18 ダウングレード Wells Fargo Overweight → Equal Weight
2020-09-17 ダウングレード Truist Buy → Hold
2020-06-01 再開されました Oppenheimer Perform
2020-05-01 ダウングレード Oppenheimer Outperform → Perform
2020-04-09 ダウングレード Evercore ISI In-line → Underperform
2020-03-05 アップグレード Wells Fargo Equal Weight → Overweight
2020-01-02 ダウングレード Evercore ISI Outperform → In-line
2019-07-29 アップグレード SunTrust Hold → Buy
2019-07-26 ダウングレード JP Morgan Overweight → Neutral
2019-07-26 ダウングレード Wedbush Outperform → Neutral
2019-03-20 開始されました SunTrust Hold
2018-11-02 ダウングレード Wells Fargo Outperform → Market Perform
2018-07-16 開始されました Evercore ISI Outperform
2018-04-18 繰り返されました Mizuho Buy
2018-02-23 繰り返されました Mizuho Buy
2017-05-24 アップグレード Wells Fargo Market Perform → Outperform
2016-07-29 繰り返されました Wedbush Outperform
2016-01-19 開始されました Barclays Underweight
2015-12-02 開始されました Deutsche Bank Hold
すべてを表示

Novocure Ltd (NVCR) 最新ニュース

pulisher
Feb 12, 2026

NovoCure (NASDAQ:NVCR) Shares Gap UpTime to Buy? - MarketBeat

Feb 12, 2026
pulisher
Feb 12, 2026

Assessing NovoCure (NVCR) Valuation After FDA Approval Of Optune Pax For Pancreatic Cancer - Yahoo Finance

Feb 12, 2026
pulisher
Feb 12, 2026

Approval for pancreatic cancer treatment boosts NovocureGlobes - Globes - Israel Business News

Feb 12, 2026
pulisher
Feb 12, 2026

HC Wainwright & Co. Raises NovoCure (NVCR) Price Target to $47 | - GuruFocus

Feb 12, 2026
pulisher
Feb 12, 2026

FDA Approves First-of-Its-Kind Device to Treat Pancreatic Cancer - GlobeNewswire Inc.

Feb 12, 2026
pulisher
Feb 12, 2026

NovoCure Stock Surges After FDA Approves Optune Pax - Benzinga

Feb 12, 2026
pulisher
Feb 12, 2026

Novocure Wins FDA Nod for Optune Pax Pancreatic Cancer Treatment - Medical Product Outsourcing

Feb 12, 2026
pulisher
Feb 12, 2026

NovoCure (NVCR) stock is trending overnight — here's what you should know - MSN

Feb 12, 2026
pulisher
Feb 12, 2026

Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Jobs Report—Micron, Novocure, Fastly In Focus (UPDATED) - Benzinga

Feb 12, 2026
pulisher
Feb 12, 2026

NovoCure stock price target raised to $47 from $39 at H.C. Wainwright By Investing.com - Investing.com India

Feb 12, 2026
pulisher
Feb 12, 2026

NovoCure stock price target raised to $47 from $39 at H.C. Wainwright - Investing.com

Feb 12, 2026
pulisher
Feb 12, 2026

NovoCure Limited's (NASDAQ:NVCR) 26% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st

Feb 12, 2026
pulisher
Feb 12, 2026

Novocure (NVCR) Shares Surge on FDA Approval for Optune Pax - GuruFocus

Feb 12, 2026
pulisher
Feb 12, 2026

U.S. Stock Futures Rise as Fastly and Novocure Surge - Intellectia AI

Feb 12, 2026
pulisher
Feb 12, 2026

Novocure shares surge after FDA approves pancreatic cancer device By Investing.com - Investing.com South Africa

Feb 12, 2026
pulisher
Feb 12, 2026

Novocure shares surge after FDA approves pancreatic cancer device - Investing.com India

Feb 12, 2026
pulisher
Feb 11, 2026

Form 8-KMaterial Events - Stock Titan

Feb 11, 2026
pulisher
Feb 11, 2026

First new pancreatic cancer treatment in nearly 30 years is wearable - Stock Titan

Feb 11, 2026
pulisher
Feb 11, 2026

Novocure shares soar 30% after FDA nod for pancreatic cancer device - Investing.com Australia

Feb 11, 2026
pulisher
Feb 11, 2026

FDA Approves Novocure's Optune Pax for Pancreatic Cancer Treatme - GuruFocus

Feb 11, 2026
pulisher
Feb 11, 2026

NovoCure Ltd treatment gains FDA approval for pancreatic cancer - Traders Union

Feb 11, 2026
pulisher
Feb 11, 2026

Novocure Ltd FDA Approval of Optune Pax for Pancreatic Cancer - TradingView

Feb 11, 2026
pulisher
Feb 11, 2026

FDA clears Novocure (NVCR) Optune Pax for locally advanced pancreatic cancer - Stock Titan

Feb 11, 2026
pulisher
Feb 11, 2026

NovoCure (NVCR) Stock Is Trending OvernightHere's What You Should Know - Bitget

Feb 11, 2026
pulisher
Feb 09, 2026

Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness In Tumor Treating Fields Story - Sahm

Feb 09, 2026
pulisher
Feb 09, 2026

HC Wainwright Has Bearish Forecast for NovoCure Q1 Earnings - Defense World

Feb 09, 2026
pulisher
Feb 06, 2026

Novocure stock hits 52-week low at $10.66 By Investing.com - Investing.com South Africa

Feb 06, 2026
pulisher
Feb 06, 2026

C WorldWide Group Holding A S Grows Position in NovoCure Limited $NVCR - MarketBeat

Feb 06, 2026
pulisher
Feb 05, 2026

Novocure stock falls after CMS revokes billing privileges By Investing.com - Investing.com South Africa

Feb 05, 2026
pulisher
Feb 05, 2026

Novocure stock falls after CMS revokes billing privileges - Investing.com

Feb 05, 2026
pulisher
Feb 05, 2026

NovoCure (NASDAQ:NVCR) Sets New 52-Week LowWhat's Next? - MarketBeat

Feb 05, 2026
pulisher
Feb 05, 2026

Novocure stock hits 52-week low at $10.66 - Investing.com

Feb 05, 2026
pulisher
Feb 05, 2026

**NovoCure Faces CMS Billing Privileges Revocation** - TradingView

Feb 05, 2026
pulisher
Jan 31, 2026

Take Profit: Is NovoCure Limited stock showing strong momentumTrade Volume Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn

Jan 31, 2026
pulisher
Jan 30, 2026

Piper Sandler reiterates Overweight rating on NovoCure stock By Investing.com - Investing.com South Africa

Jan 30, 2026
pulisher
Jan 30, 2026

Piper Sandler reiterates Overweight rating on NovoCure stock - Investing.com

Jan 30, 2026
pulisher
Jan 29, 2026

Hussman Strategic Advisors Inc. Takes $1.09 Million Position in NovoCure Limited $NVCR - MarketBeat

Jan 29, 2026
pulisher
Jan 27, 2026

NovoCure Limited (NVCR) Stock Analysis: An Investor’s Look at 81.53% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews

Jan 27, 2026
pulisher
Jan 24, 2026

Emerald Mutual Fund Advisers Trust Has $248,000 Stock Position in NovoCure Limited $NVCR - MarketBeat

Jan 24, 2026
pulisher
Jan 20, 2026

NovoCure Limited (NVCR): Investor Outlook on a 76% Potential Upside in Medical Device Innovation - DirectorsTalk Interviews

Jan 20, 2026
pulisher
Jan 19, 2026

NovoCure Limited (NASDAQ:NVCR) Short Interest Update - MarketBeat

Jan 19, 2026
pulisher
Jan 16, 2026

NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of “Hold” from Analysts - Defense World

Jan 16, 2026
pulisher
Jan 16, 2026

NovoCure’s (NVCR) “Neutral” Rating Reaffirmed at Wedbush - Defense World

Jan 16, 2026
pulisher
Jan 15, 2026

Assessing NovoCure: Insights From 4 Financial Analysts - Benzinga

Jan 15, 2026
pulisher
Jan 15, 2026

NovoCure (NVCR) Rating Reiterated as Neutral by Wedbush | NVCR S - GuruFocus

Jan 15, 2026
pulisher
Jan 15, 2026

A Look At NovoCure (NVCR) Valuation After Record 2025 Revenue And CEO Transition - simplywall.st

Jan 15, 2026
pulisher
Jan 15, 2026

NovoCure (NASDAQ:NVCR) Receives Neutral Rating from Wedbush - MarketBeat

Jan 15, 2026
pulisher
Jan 15, 2026

HC Wainwright Has Bullish Estimate for NovoCure Q4 Earnings - MarketBeat

Jan 15, 2026
pulisher
Jan 15, 2026

Leerink Partners Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $24 - Futubull

Jan 15, 2026
pulisher
Jan 15, 2026

NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of "Hold" from Analysts - MarketBeat

Jan 15, 2026
pulisher
Jan 15, 2026

Brokers Set Expectations for NovoCure FY2030 Earnings - Defense World

Jan 15, 2026

Novocure Ltd (NVCR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
medical_devices ZBH
$95.18
price down icon 0.45%
medical_devices STE
$244.22
price up icon 0.31%
$65.08
price down icon 4.50%
medical_devices PHG
$31.41
price down icon 2.06%
$78.65
price down icon 0.69%
medical_devices EW
$76.44
price down icon 3.64%
大文字化:     |  ボリューム (24 時間):